Following more than a decade of development, the Chinese biotech sector is producing attractive drug candidates at an historic pace, and multinational pharmaceutical companies are increasingly seeking access to these assets to solve impending patent cliffs.

Market Overview

China's biotech sector has seen rapid growth in the last decade and has established itself as a leading hub for drug innovation.  Global pharmaceuticals have taken notice.  China is no longer viewed solely as a strategically important market in which to sell and manufacture innovative drugs. Today, China's cost-efficient and fast-paced innovation has resulted in Chinese biotech companies  partnering with multinational pharmaceuticals to develop and market critical new drug candidates.

Some reports estimate that the Chinese biotech sector is already responsible for nearly 30% of the global innovative drug pipeline and that the value of drugs licensed from China to the West already totals nearly $50 billion.  A recent study estimated that 30% or more of global biotech patents originate in China.

A rise in cross-border deal-making has followed in the wake of these new opportunities. Private equity and venture capital firms are allocating funds to the sector, and Chinese biotechs are accessing further growth capital through a robust IPO market in Hong Kong. These investments are paying off handsomely as out-licensing deals with substantial upfront payments are becoming more common with various reports indicating that Chinese companies signed more than 125 out-licensing deals in 2025, which reflected an 81% increase over 2024 and an over 300% increase since 2020.  In 2025, nearly every major pharmaceutical company had at least one transaction involving Chinese biotech assets through licensing deals, asset acquisitions and private and public company acquisitions.

China's Proactive Biotech Development Program

Leveraging its long experience providing contract research, manufacturing and early clinical development services, China has implemented educational, regulatory and policy changes to foster the rapid development of Chinese biotechs capable of developing innovative medicinal discoveries. 

o  China invested in education. Chinese biotechs benefit from an extremely well-educated workforce with a rapidly growing number of STEM Ph.D. graduates.

o  China introduced regulatory changes to enhance Chinese drug development.  With streamlined regulatory pathways, including accession to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use and significant expansion of the workforce at the National Medical Products Administration (NMPA), the cost and speed at which novel drug candidates can be developed and validated has been recognized by many as an advantage for partnering with Chinese biotech companies.

o  China developed a financial ecosystem to support early stage biotechs.   Public funding has played an important role with more than a dozen biotech innovation hubs established in China. With the Hong Kong Main Board Listing Rules amended in 2018 to allow pre-revenue, pre-profit biotech companies to list, new players have been able to access private sector funds to finance their further growth.

The result of these policy decisions has been to create a robust Chinese biotech industry that has ready access to public and private investment and is able to identify and validate new drug innovations quickly and efficiently.  The success that Chinese biotechs have already had in developing innovative drugs, and being paid handsomely for such innovations, is expected to further strengthen the Chinese biotech ecosystem and lead to accelerated growth in the years to come.  

Policy and regulatory developments outside China

Governments in the US, Europe and the UK have introduced or considered legislative and regulatory measures intended to support domestic innovation capacity and to address strategic dependencies in response to China's rising status in the biotech sector.

o   US Support for Domestic Biotechs.  FDA has recently announced and implemented a number of reforms designed to make the US biotech industry more competitive globally.  In particular, FDA has announced reforms focused on  modernizing clinical trials, reducing animal testing, leveraging AI, and strengthening accelerated approval pathways. At the same time, the US has focused on steps to protect its domestic biotech industry by passing the BIOSECURE Act and the COINS Act, implementing the Department of Justice's Bulk Data Rule, and suggesting that the Department of Treasury's Outbound Investment Security Program (OSIP) may be expanded to cover investments in the biotechnology industry.  On February 26, 2026, a letter was issued from a group of Republican members of the House and Senate to Treasury Secretary Bessent encouraging the administration to expand the OISP to cover biotechnology.

o   European Regulatory Enhancements.  In January 2026, the Heads of Medicines Agencies in the EU confirmed the launch of a fast-track authorization pathway for certain clinical trials, scheduled to take effect in the first quarter of 2026.  This initiative marks a significant shift in Europe's clinical research policy, with the clear objective of improving the speed and competitiveness of Europe's early-stage and innovative clinical development.

o   UK's Re-focus on Life Sciences. In 2025 the UK Government affirmed its commitment to grow the UK life sciences industry to be the world's third life sciences economy by 2035 behind the US and China. It aims to achieve this through removing existing development and clinical barriers, leveraging efficiencies from a centralized national health service and faster clinical trial schemes, enticing greater investment from home and abroad, and leading in new treatments and technologies through its digital strategy and focus on genomics and personalized medicines.

The extent to which these developments will influence the pace and direction of China’s biotech growth remains uncertain. China has established itself as a significant player in the global competition to develop innovative medicinal products efficiently and cost-effectively and it's reasonable to expect China to play an increasingly important role in global drug development and partnering activity.

Deepening Engagement with Chinese Biotech

To date the commercial response to the rise of Chinese biotech has been the rapidly increasing number of transactions to license, invest in and acquire promising drug candidates originating from China.  Absent further geopolitical reactions, many global investors and pharmaceutical companies will seek to develop a more robust presence in the Chinese biotech community to gain earlier access to new investment opportunities and to better discern between the good and bad opportunities. 

In the near term, global investors and dealmakers have to grapple with challenges in cross-border transactions with Chinese counterparties due to, among other things, significant differences in legal systems and a plethora of regulations in various jurisdictions on movement of technology, materials and information beyond national borders. More importantly, multinational pharmaceutical companies will need to consider how best to structure their own long-term innovation strategies in China, including whether to expand local R&D capabilities, deepen partnership networks, or continuing to rely primarily on external opportunities. Over time, the continued development of China’s biotech sector may enable more Chinese pharmaceutical companies to commercialize products globally with less reliance on established multinational partners. If so, companies that have not established a meaningful presence or partnering strategy in China may find access to China-originated innovation becoming more competitive and more limited.